This research paper discusses the use of molecular imaging, particularly positron emission tomography (PET), to enhance precision oncology in breast cancer by enabling early response assessment and predicting treatment outcomes. It highlights novel applications of PET imaging biomarkers, including those for glucose metabolism and steroid receptors, to improve treatment success and minimize side effects.